Loteprednol etabonate controls inflammation and IOP

Loteprednol etabonate controls inflammation and reduces IOP fluctuation after cataract surgery, according to a recent study.

The comparative case series, led by Dr S. Lane, Associated Eye Care, Stillwater, Minnesota, USA, involved 88 patients. Loteprednol etabonate was given to 46 patients and prednisolone acetate was given to 42 patients. Both sets of patients also received bromfenac 0.09% and besifloxacin 0.6% after surgery.

Patients were excluded from the study if they had pre-existing medical conditions such as elevated IOP, retinopathy, maculopathy or uveitis. The outcome measures included visual acuity, IOP, and anterior chamber cell and flare intensity. The primary endpoint was the level of anterior chamber cell and flare intensity in all patients.

The two groups achieved equivalency with no significant differences throughout the 3-week follow-up period. Loteprednol etabonate reduced IOP fluctuation, compared to patients treated with prednisolone acetate. However, both treatment groups presented with controlled inflammation after cataract surgery.

The abstract can be found in the Journal of Cataract and Refractive Surgery.